28.29
Schlusskurs vom Vortag:
$27.75
Offen:
$28.305
24-Stunden-Volumen:
9,489
Relative Volume:
0.34
Marktkapitalisierung:
$9.86B
Einnahmen:
$136.33M
Nettoeinkommen (Verlust:
$-56.34M
KGV:
-37.70
EPS:
-0.7504
Netto-Cashflow:
$-18.87M
1W Leistung:
+15.82%
1M Leistung:
+11.03%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Firmenname
Ascentage Pharma Group International Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie AAPG mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
AAPG
Ascentage Pharma Group International Adr
|
28.29 | 2.13B | 136.33M | -56.34M | -18.87M | -0.7504 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-27 | Eingeleitet | JP Morgan | Overweight |
Ascentage Pharma Group International Adr Aktie (AAPG) Neueste Nachrichten
Ascentage Pharma Unveils Promising Data on Alrizomadlin at ASCO 2025 - TipRanks
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - GlobeNewswire Inc.
Ascentage Pharma Announces Successful AGM Resolutions on May 19, 2025 - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting By Investing.com - Investing.com South Africa
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting - Investing.com
JPMorgan sets Ascentage Pharma stock to Overweight, $27 target - Investing.com
Takeda Pharmaceutical Company (TKPYY) Stock: Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Ascentage Pharma to Announce 2024 Financial Results and Corporate Update - TipRanks
Avoid the Trap: 3 High-yield Dividend Stocks With Safe Payouts - The Globe and Mail
Ascentage Pharma IPO opens flat - Investing.com
Ascentage Pharma shares slide ahead of ADS debut on Nasdaq - Investing.com
Ascentage prices first biotech IPO of 2025, raising $126M - BioPharma Dive
Ascentage Pharma sets terms for $149 million US IPO - The Pharma Letter
Takeda-backed Ascentage Pharma files for $100M IPO (IPO:NYSEARCA) - Seeking Alpha
Market Capitalization: What It Is, Formula for Calculating It - Investopedia
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares - PR Newswire
Takeda, Ascentage Pharma Sign Option Agreement - Contract Pharma
BIIB Stock Quote Price and Forecast - CNN
Capital Markets - Wilson Sonsini
Morningstar | Empowering Investor Success - Morningstar
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN Logo
Finanzdaten der Ascentage Pharma Group International Adr-Aktie (AAPG)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):